Targeted Prevention for Non-Melanoma Skin Cancer

非黑色素瘤皮肤癌的针对性预防

基本信息

  • 批准号:
    10410013
  • 负责人:
  • 金额:
    $ 23.45万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2019
  • 资助国家:
    美国
  • 起止时间:
    2019-09-10 至 2024-08-31
  • 项目状态:
    已结题

项目摘要

ABSTRACT Overall Targeted Prevention of Non-Melanoma Skin Cancer Skin cancer is the most common malignancy worldwide. One out of three new cancers is a skin cancer. Approximately 5 million cases of non-melanoma skin cancer (NMSC) – basal cell carcinoma (BCC) and cutaneous squamous cell carcinomas (cSCC) occur annually. Incidence rates for NMSC continue to rise, creating a substantial impact on morbidity and health care costs that account for $8.1 billion/year for skin cancer treatment. The majority of these lesions represent keratinocytic neoplasms. The overall goal of this multi- institutional Program Project Grant (PPG) is to employ novel technologies and develop new targeted prevention strategies to eradicate intraepithelial neoplasias in the skin (e.g. actinic keratosis, squamous cell carcinoma in situ), and thereby, to dramatically reduce the risk of cSCC. To achieve this goal, we will conduct a multilevel program of rational drug development, including: 1) to assess, in experimental models and human studies, the significance of TLR4 and TOPK/PRPK signaling pathways in skin carcinogenesis leading to cSCC development; 2) to evaluate the relationship between TLR4 and TOPK/PRPK activation and previously established signaling pathways of relevance in AK and cSCC development; 3) to identify and develop novel therapeutic preventive agents that specifically “hit” these molecular targets in cSCC mouse models and effectively modulate their signaling pathways; 4) to test the most promising target-specific agents in preclinical pharmacology models; and 5) to assess target engagement and safety of selected agents through pilot and Phase 1 clinical trials. Knowledge of the key molecular targets in solar ultraviolet (UV) radiation signaling pathways and the development of multiple topically administered agents that can hit and effectively modulate these targets ultimately will allow for precision medicine based approaches in cSCC prevention. While the two basic science projects (Projects 1 and 2) aim to identify and validate UV-induced signaling pathways and agents that modulate these targets, the clinical project (Project 3) will undertake the task of moving leading candidate drugs from mouse models into acute solar simulated light studies and Phase 1 clinical trials. Novel technologies include signaling network analysis using state-of-the-art proteomic arrays and whole transcriptome analysis coupled with the latest exploratory and downstream bioinformatic approaches and in vivo reflectance confocal microscopy for non-invasive assessment and selection of tissue samples in human skin. This highly integrated and translational research based program project, emphasizing a multidisciplinary, precision medicine approach for the prevention of cSCC of the skin can also serve as a model for preventing other epithelial malignancies.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Clara Curiel-Lewandrowski其他文献

Clara Curiel-Lewandrowski的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Clara Curiel-Lewandrowski', 18)}}的其他基金

Project 3: Translational Studies and Clinical Pharmacology of TLR4 and TOPK Inhibitors for Prevention of Squamous Cell Carcinoma of the Skin
项目3:TLR4和TOPK抑制剂预防皮肤鳞状细胞癌的转化研究和临床药理学
  • 批准号:
    10410014
  • 财政年份:
    2019
  • 资助金额:
    $ 23.45万
  • 项目类别:
Core A: Administration
核心A:管理
  • 批准号:
    10686374
  • 财政年份:
    2019
  • 资助金额:
    $ 23.45万
  • 项目类别:
Targeted Prevention for Non-Melanoma Skin Cancer
非黑色素瘤皮肤癌的针对性预防
  • 批准号:
    10015212
  • 财政年份:
    2019
  • 资助金额:
    $ 23.45万
  • 项目类别:
Project 3: Translational Studies and Clinical Pharmacology of TLR4 and TOPK Signaling Pathway Inhibitors for Prevention of Squamous Cell Carcinoma of the Skin
项目3:TLR4和TOPK信号通路抑制剂预防皮肤鳞状细胞癌的转化研究和临床药理学
  • 批准号:
    10252871
  • 财政年份:
    2019
  • 资助金额:
    $ 23.45万
  • 项目类别:
Core A: Administration
核心A:管理
  • 批准号:
    10268445
  • 财政年份:
    2019
  • 资助金额:
    $ 23.45万
  • 项目类别:
Project 3: Translational Studies and Clinical Pharmacology of TLR4 and TOPK Signaling Pathway Inhibitors for Prevention of Squamous Cell Carcinoma of the Skin
项目3:TLR4和TOPK信号通路抑制剂预防皮肤鳞状细胞癌的转化研究和临床药理学
  • 批准号:
    10475143
  • 财政年份:
    2019
  • 资助金额:
    $ 23.45万
  • 项目类别:
Core A: Administration
核心A:管理
  • 批准号:
    10493964
  • 财政年份:
    2019
  • 资助金额:
    $ 23.45万
  • 项目类别:
Project 3: Translational Studies and Clinical Pharmacology of TLR4 and TOPK Signaling Pathway Inhibitors for Prevention of Squamous Cell Carcinoma of the Skin
项目3:TLR4和TOPK信号通路抑制剂预防皮肤鳞状细胞癌的转化研究和临床药理学
  • 批准号:
    10015218
  • 财政年份:
    2019
  • 资助金额:
    $ 23.45万
  • 项目类别:
Core A: Administration
核心A:管理
  • 批准号:
    10015219
  • 财政年份:
    2019
  • 资助金额:
    $ 23.45万
  • 项目类别:
Core A: Administration
核心A:管理
  • 批准号:
    10475149
  • 财政年份:
    2019
  • 资助金额:
    $ 23.45万
  • 项目类别:

相似海外基金

Blood transcriptomics as CT adjuvant to exclude hemorrhage in acute stroke
血液转录组学作为 CT 佐剂排除急性中风出血
  • 批准号:
    10611988
  • 财政年份:
    2020
  • 资助金额:
    $ 23.45万
  • 项目类别:
Blood transcriptomics as CT adjuvant to exclude hemorrhage in acute stroke
血液转录组学作为 CT 佐剂排除急性中风出血
  • 批准号:
    10396630
  • 财政年份:
    2020
  • 资助金额:
    $ 23.45万
  • 项目类别:
Blood transcriptomics as CT adjuvant to exclude hemorrhage in acute stroke
血液转录组学作为 CT 佐剂排除急性中风出血
  • 批准号:
    10210310
  • 财政年份:
    2020
  • 资助金额:
    $ 23.45万
  • 项目类别:
An Evaluation of Adjuvant Treatments to Mechanical Ventilation for Acute Respiratory Failure
机械通气治疗急性呼吸衰竭辅助治疗的评价
  • 批准号:
    319456
  • 财政年份:
    2014
  • 资助金额:
    $ 23.45万
  • 项目类别:
    Fellowship Programs
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    6566709
  • 财政年份:
    2001
  • 资助金额:
    $ 23.45万
  • 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    6413648
  • 财政年份:
    2000
  • 资助金额:
    $ 23.45万
  • 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    6305272
  • 财政年份:
    1999
  • 资助金额:
    $ 23.45万
  • 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    6115194
  • 财政年份:
    1998
  • 资助金额:
    $ 23.45万
  • 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    6276403
  • 财政年份:
    1997
  • 资助金额:
    $ 23.45万
  • 项目类别:
ACUTE OTITIS MEDIA--ADJUVANT THERAPY TO IMPROVE OUTCOME
急性中耳炎——改善疗效的辅助治疗
  • 批准号:
    6276429
  • 财政年份:
    1997
  • 资助金额:
    $ 23.45万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了